Page last updated: 2024-11-13

azd3839

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

AZD3839: a BACE1 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46202416
CHEMBL ID2177913
SCHEMBL ID1358337
MeSH IDM0581179

Synonyms (33)

Synonym
azd3839
azd-3839
azd 3839
chembl2177913 ,
bdbm50398264
S7731
SCHEMBL1358337
azd 3839 [who-dd]
(1s)-1-(2-(difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1h-isoindol-3-amine
unii-i8id590133
I8ID590133 ,
1h-isoindol-3-amine, 1-(2-(difluoromethyl)-4-pyridinyl)-4-fluoro-1-(3-(5-pyrimidinyl)phenyl)-, (1s)-
1227163-84-9
HY-13438
azd3839 (free base)
CS-5933
(s)-1-(2-(difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1h-isoindol-3-amine
DB12368
(1s)-1-[2-(difluoromethyl)pyridin-4-yl]-4-fluoro-1-[3-(pyrimidin-5-yl)phenyl]-1h-isoindol-3-amine
AKOS032945038
azd3839 free base
azd-3839; azd 3839
BCP23892
(3s)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine
EX-A2576
BS-15015
HMS3886L17
CCG-269020
Q27280573
F85452
NCGC00481568-01
c24h16f3n5
AC-36154

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" AZD3839 exposure displayed non-linear kinetics, described by a three-compartment model with a saturated binding compartment and an increase in bioavailability with dose."( Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers.
Alexander, R; Bueters, T; Claeson-Bohnstedt, K; Fälting, J; Huledal, G; Karlsson, P; Lee, CM; Lüttgen, M; Maltby, J; Olsson, T; Paraskos, J; Paulsson, B; Quartino, A; Sparve, E, 2014
)
1.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-secretase 1Homo sapiens (human)IC50 (µMol)0.01750.00061.619410.0000AID1480281; AID707150; AID707151
Beta-secretase 1Homo sapiens (human)Ki0.02570.00031.35248.0000AID1380355
Beta-secretase 1Mus musculus (house mouse)IC50 (µMol)0.05100.01070.06260.1260AID706964
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)4.80000.00091.901410.0000AID707147
Beta-secretase 2Homo sapiens (human)IC50 (µMol)0.00090.00090.64922.8800AID1480282
Beta-secretase 2Homo sapiens (human)Ki0.37000.00160.12490.3700AID707139
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
proteolysisBeta-secretase 1Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 1Homo sapiens (human)
response to lead ionBeta-secretase 1Homo sapiens (human)
protein processingBeta-secretase 1Homo sapiens (human)
amyloid-beta formationBeta-secretase 1Homo sapiens (human)
amyloid precursor protein catabolic processBeta-secretase 1Homo sapiens (human)
positive regulation of neuron apoptotic processBeta-secretase 1Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painBeta-secretase 1Homo sapiens (human)
prepulse inhibitionBeta-secretase 1Homo sapiens (human)
cellular response to copper ionBeta-secretase 1Homo sapiens (human)
cellular response to manganese ionBeta-secretase 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionBeta-secretase 1Homo sapiens (human)
signaling receptor ligand precursor processingBeta-secretase 1Homo sapiens (human)
cellular response to amyloid-betaBeta-secretase 1Homo sapiens (human)
amyloid fibril formationBeta-secretase 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
proteolysisBeta-secretase 2Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 2Homo sapiens (human)
protein processingBeta-secretase 2Homo sapiens (human)
peptide hormone processingBeta-secretase 2Homo sapiens (human)
melanosome organizationBeta-secretase 2Homo sapiens (human)
glucose homeostasisBeta-secretase 2Homo sapiens (human)
negative regulation of amyloid precursor protein biosynthetic processBeta-secretase 2Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
amyloid-beta bindingBeta-secretase 1Homo sapiens (human)
endopeptidase activityBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 1Homo sapiens (human)
protein bindingBeta-secretase 1Homo sapiens (human)
peptidase activityBeta-secretase 1Homo sapiens (human)
beta-aspartyl-peptidase activityBeta-secretase 1Homo sapiens (human)
enzyme bindingBeta-secretase 1Homo sapiens (human)
protein serine/threonine kinase bindingBeta-secretase 1Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 2Homo sapiens (human)
protein bindingBeta-secretase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
lysosomeBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
early endosomeBeta-secretase 1Homo sapiens (human)
late endosomeBeta-secretase 1Homo sapiens (human)
multivesicular bodyBeta-secretase 1Homo sapiens (human)
endoplasmic reticulum lumenBeta-secretase 1Homo sapiens (human)
Golgi apparatusBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
synaptic vesicleBeta-secretase 1Homo sapiens (human)
cell surfaceBeta-secretase 1Homo sapiens (human)
endosome membraneBeta-secretase 1Homo sapiens (human)
membraneBeta-secretase 1Homo sapiens (human)
axonBeta-secretase 1Homo sapiens (human)
dendriteBeta-secretase 1Homo sapiens (human)
neuronal cell bodyBeta-secretase 1Homo sapiens (human)
membrane raftBeta-secretase 1Homo sapiens (human)
recycling endosomeBeta-secretase 1Homo sapiens (human)
Golgi-associated vesicle lumenBeta-secretase 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
endoplasmic reticulumBeta-secretase 2Homo sapiens (human)
Golgi apparatusBeta-secretase 2Homo sapiens (human)
plasma membraneBeta-secretase 2Homo sapiens (human)
membraneBeta-secretase 2Homo sapiens (human)
melanosome membraneBeta-secretase 2Homo sapiens (human)
plasma membraneBeta-secretase 2Homo sapiens (human)
trans-Golgi networkBeta-secretase 2Homo sapiens (human)
endosomeBeta-secretase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID707146Intrinsic clearance in rat hepatocytes assessed per 10'6 cells2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707140Inhibition of notch2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707143Lipophilicity, log D of the compound by RP-HPLC analysis2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID1480281Inhibition of recombinant human BACE1 (1 to 460 residues) using CEVNLDAEFK as substrate preincubated for 10 mins followed by substrate addition measured after 6.5 hrs by TR-FRET assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Toward β-Secretase-1 Inhibitors with Improved Isoform Selectivity.
AID1480274Inhibition of BACE2 in human MNT1 cells assessed as increase in M-beta accumulation at 10 nM after 24 hrs by Western blot method2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Toward β-Secretase-1 Inhibitors with Improved Isoform Selectivity.
AID706936Antialzheimer activity in C57BL/6 mouse assessed as reduction in sAPPbeta level in brain at 80 umol/kg, po2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707139Inhibition of human recombinant BACE2 using (europium)CEVNLDAEFK(Qsy7) as substrate incubated for 10 mins prior to substrate addition measured after 15 mins by TR-FRET assay2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID706916Ratio of free drug concentration in brain to free drug concentration in plasma in C57BL/6 mouse at 80 umol/kg, po at 1.5 hrs2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID706942Antialzheimer activity in C57BL/6 mouse assessed as reduction in amyloid beta 42 level in brain at 80 umol/kg, po2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID706923Free drug concentration in C57BL/6 mouse brain at 80 umol/kg, po at 1.5 hrs2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707150Inhibition of BACE1 in human SH-SY5Y cells assessed as inhibition of sAPPbeta release after 16 hrs by immunoassay2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707147Inhibition of human ERG expressed in CHO cells by IonWorks assay2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID706950Fraction unbound in C57BL/6 mouse brain at 80 umol/kg, po2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID1380355Inhibition of human BACE1 (1 to 460 residues) preincubated for 10 mins followed by (Europium)CEVNLDAEFK(Qsy7) substrate addition measured after 6.5 hrs by TR-FRET assay2018Journal of medicinal chemistry, 08-09, Volume: 61, Issue:15
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
AID706929Free drug concentration in C57BL/6 mouse plasma at 80 umol/kg, po at 1.5 hrs2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID706955Fraction unbound in C57BL/6 mouse plasma at 80 umol/kg, po2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707149Apparent permeability from apical to basal side of human Caco2 cells at 10 uM after 60 mins by LC/MS analysis2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID706964Inhibition of BACE1-mediated amyloid beta 40 release in C57/BL6 mouse primary cortical neurons after overnight incubation by ELISA2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707144Selectivity ratio of IC50 for human ERG to IC50 for BACE1 in human SH-SY5Y cells2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707142Oral bioavailability in mouse2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707151Inhibition of human recombinant BACE1 using (europium)CEVNLDAEFK(Qsy7) as substrate incubated for 10 mins prior to substrate addition measured after 15 mins by TR-FRET assay2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707145Dissociation constant, pKa of the compound by pressure-assisted capillary electrophoretic analysis2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707141Half life in po dosed mouse2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID706962Antialzheimer activity in C57BL/6 mouse assessed as reduction in amyloid beta 40 level in brain at 80 umol/kg, po at 1.5 hrs by ELISA relative to control2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID707148Efflux ratio of apparent permeability from basal to apical to apical to basal side of human Caco2 cells at 10 uM after 60 mins by LC/MS analysis2012Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21
Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
AID1480282Inhibition of human BACE2 (1 to 473 residues) using CEVNLDAEFK as substrate preincubated for 10 mins followed by substrate addition measured after 6.5 hrs by TR-FRET assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Toward β-Secretase-1 Inhibitors with Improved Isoform Selectivity.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (88.89)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.70 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (22.22%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]